Rosuvastatin Calcium Tablet, Coated
FDA Label NDC 51655-756

34 label sections · Submitted to the FDA by Northwind Health Company, Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Northwind Health Company, Llc for the product Rosuvastatin Calcium (NDC 51655-756). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 2.1 general dosage and administration information, 2.2 recommended dosage in adult patients, 2.3 recommended dosage in pediatric patients, 2.4 dosing in asian patients, 2.5 recommended dosage in patients with renal impairment, 2.6 dosage modifications due to drug interactions, other, 5.1 myopathy and rhabdomyolysis, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

2.1 General Dosage And Administration Information

• Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food. Swallow the tablets whole.
• Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets, and adjust the dosage if necessary.

• If a dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose.

• When taking rosuvastatin tablets with an aluminum and magnesium hydroxide combination antacid, administer rosuvastatin tablets at least 2 hours before the antacid [see Drug Interactions ( 7.2) ] .

• The dosage range for rosuvastatin tablets are 5 to 40 mg orally once daily.
• The recommended dose of rosuvastatin tablets depend on a patient’s indication for usage, LDL-C, and individual risk for CV events.

2.3 Recommended Dosage In Pediatric Patients

Dosage in Pediatric Patients 8 Years of Age and Older with HeFH
The recommended dosage range is 5 mg to 10 mg orally once daily in patients aged 8 years to less than 10 years and 5 mg to 20 mg orally once daily in patients aged 10 years and older.

Dosage in Pediatric Patients 7 Years of Age and Older with HoFH
The recommended dosage is 20 mg orally once daily.

2.4 Dosing In Asian Patients

Initiate rosuvastatin tablets at 5 mg once daily due to increased rosuvastatin plasma concentrations. Consider the risks and benefits of rosuvastatin tablets when treating Asian patients not adequately controlled at doses up to 20 mg once daily [ see Warnings and Precautions ( 5.1), Use in Specific Populations ( 8.8) , and Clinical Pharmacology ( 12.3) ].

In patients with severe renal impairment (CL crless than 30 mL/min/1.73 m 2) not on hemodialysis, the recommended starting dosage is 5 mg once daily and should not exceed 10 mg once daily [ see Warnings and Precautions ( 5.1) and Use in Specific Populations ( 8.6) ].

There are no dosage adjustment recommendations for patients with mild and moderate renal impairment.

2.6 Dosage Modifications Due To Drug Interactions

Table 1 displays dosage modifications for rosuvastatin tablets due to drug interactions [ see Warnings and Precautions ( 5.1) and Drug Interactions ( 7.1) ].

Table 1: Rosuvastatin Tablets Dosage Modifications Due to Drug Interactions

Concomitantly Used Drug

Rosuvastatin tablets Dosage Modifications 

Cyclosporine

Do not exceed 5 mg once daily.

Teriflunomide

Do not exceed 10 mg once daily.

Enasidenib

Do not exceed 10 mg once daily.

Capmatinib

Do not exceed 10 mg once daily.

Fostamatinib

Do not exceed 20 mg once daily.

Febuxostat

Do not exceed 20 mg once daily.

Gemfibrozil

Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 10 mg once daily.

Tafamidis

Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 20 mg once daily.

Antiviral Medications

o Sofbuvir/velpatasvir/voxilaprevir 

o Ledipasvir/sofosbuvir

Concomitant use not recommended.

o Simeprevir

oDasabuvir/ombitasvir/paritaprevir/ritonavir

o Elbasvir/Grazoprevir

o Sofosbuvir/Velpatasvir

o Glecaprevir/Pibrentasvir

o Atazanavir/Ritonavir 

o Lopinavir/Ritonavir

Initiate at 5 mg once daily. Do not exceed 10 mg once daily. 

Darolutamide

Do not exceed 5 mg once daily.

Regorafenib 

Do not exceed 10 mg once daily.

Other

• 5 mg: Yellow colored, round, biconvex, film coated tablets debossed with ‘79’ on one side and plain on other side.

• 10 mg: Light pink colored, round, biconvex, film coated tablets debossed with ‘1180’ on one side and plain on other side.

• 20 mg: Light pink colored, round, biconvex, film coated tablets debossed with ‘1181’ on one side and plain on other side.

• 40 mg: Light pink colored, oval shape, biconvex, beveled edge, film coated tablets debossed with ‘1182’ on one side and plain on other side.

Rosuvastatin tablets are contraindicated in the following conditions:
• Acute liver failure or decompensated cirrhosis [see Warnings and Precautions ( 5.3) ] .
• Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin tablets. [see Adverse Reactions ( 6.1) ] .

The following important adverse reactions are described below and elsewhere in the labeling:
Myopathy and Rhabdomyolysis [ see Warnings and Precautions (5.1)]
Immune-Mediated Necrotizing Myopathy [ see Warnings and Precautions (5.2)]
Hepatic Dysfunction [ see Warnings and Precautions (5.3)]
Proteinuria and Hematuria [ see Warnings and Precautions (5.4)]
Increases in HbA1c and Fasting Serum Glucose Levels [ see Warnings and Precautions (5.5)]

5.1 Myopathy And Rhabdomyolysis

Rosuvastatin tablets may cause myopathy [muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK)] and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis with statins, including rosuvastatin tablets.

Risk Factors for Myopathy

Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher rosuvastatin tablets dosage. Asian patients on rosuvastatin tablets may be at higher risk for myopathy [ see Drug Interactions ( 7.1) and  Use in Specific Populations ( 8.8) ]. The myopathy risk is greater in patients taking rosuvastatin tablets 40 mg daily compared with lower rosuvastatin tablets dosages.

Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis

The concomitant use of rosuvastatin tablets with cyclosporine or gemfibrozil is not recommended. rosuvastatin tablets dosage modifications are recommended for patients taking certain antiviral medications, darolutamide, and regorafenib [ seeDosage and Administration ( 2.6) ]. Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis [ seeDrug Interactions ( 7.1) ].

Discontinue rosuvastatin tablets if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if rosuvastatin tablets are discontinued. Temporarily discontinue rosuvastatin tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).

Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the rosuvastatin tablets dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

5.2 Immune-Mediated Necrotizing Myopathy

There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Discontinue rosuvastatin tablets if IMNM is suspected.

5.3 Hepatic Dysfunction

Increases in serum transaminases have been reported with use of rosuvastatin tablets [ see Adverse Reactions ( 6.1) ]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy. In a pooled analysis of placebo-controlled trials, increases in serum transaminases to more than three times the ULN occurred in 1.1% of patients taking rosuvastatin tablets versus 0.5% of patients treated with placebo. Marked persistent increases of hepatic transaminases have also occurred with rosuvastatin tablets. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including rosuvastatin tablets.

Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [ seeUse in Specific Populations ( 8.7) ].

Consider liver enzyme testing before rosuvastatin tablets initiation and when clinically indicated thereafter. Rosuvastatin tablets are contraindicated in patients with acute liver failure or decompensated cirrhosis [ see Contraindications ( 4) ]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue rosuvastatin tablets.

5.4 Proteinuria And Hematuria

In the rosuvastatin tablets clinical trial program, dipstick-positive proteinuria and microscopic hematuria were observed among rosuvastatin tablets treated patients. These findings were more frequent in patients taking rosuvastatin tablets 40 mg, when compared to lower doses of rosuvastatin tablets or comparator statins, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, consider a dose reduction for patients on rosuvastatin tablets therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing.

5.5 Increases In Hba1c And Fasting Serum Glucose Levels

Increases in HbA1c and fasting serum glucose levels have been reported with statins, including rosuvastatin tablets. Based on clinical trial data with rosuvastatin tablets, in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus [ see Adverse Reactions ( 6.1) ]. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse reactions reported in ≥2% of patients in placebo-controlled clinical studies and at a rate greater than placebo are shown in Table 2. These studies had a treatment duration of up to 12 weeks.

Table 2: Adverse Reactions Reported in ≥2% of Patients Treated with Rosuvastatin Tablets and > Placebo in Placebo-Controlled Trials

Adverse
Reactions
Placebo
N=382%

Rosuvastatin tablets 

5 mg
N=291%

Rosuvastatin tablets 

10 mg
N=283%

Rosuvastatin tablets 20 mg
N=64%
Rosuvastatin tablets 40 mg
N=106%
Total Rosuvastatin tablets
5 mg to 40 mg
N=744%
Headache5.05.54.93.18.55.5
Nausea3.13.83.56.303.4
Myalgia1.33.12.16.31.92.8
Asthenia2.62.43.24.70.92.7
Constipation2.42.12.14.72.82.4

Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity (including rash, pruritus, urticaria, and angioedema) and pancreatitis. The following laboratory abnormalities have also been reported: dipstick-positive proteinuria and microscopic hematuria; elevated creatine phosphokinase, transaminases, glucose, glutamyl transpeptidase, alkaline phosphatase, and bilirubin; and thyroid function abnormalities.

In the METEOR study, patients were treated with rosuvastatin tablets 40 mg (n=700) or placebo (n=281) with a mean treatment duration of 1.7 years. Adverse reactions reported in ≥2% of patients and at a rate greater than placebo are shown in Table 3.

Table 3: Adverse Reactions Reported in ≥2% of Patients Treated with Rosuvastatin Tablets and > Placebo in the METEOR Trial

1 Frequency recorded as abnormal laboratory value.

Adverse ReactionsPlacebo
N=281%
Rosuvastatin tablets 40 mg
N=700%
Myalgia12.112.7
Arthralgia7.110.1
Headache5.36.4
Dizziness2.84.0
Increased CPK0.72.6
Abdominal pain1.82.4
ALT greater than 3x ULN 10.72.2

In the JUPITER study, patients were treated with rosuvastatin tablets 20 mg (n=8,901) or placebo (n=8,901) for a mean duration of 2 years. In JUPITER, there was a significantly higher frequency of diabetes mellitus reported in patients taking rosuvastatin tablets (2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in rosuvastatin tablets-treated patients compared to placebo-treated patients. The number of patients with a HbA1c >6.5% at the end of the trial was significantly higher in rosuvastatin tablets-treated versus placebo-treated patients [see Clinical Studies (14)].

Adverse reactions reported in ≥2% of patients and at a rate greater than placebo are shown in Table 4.

Table 4: Adverse Reactions Reported in ≥2% of Patients Treated with Rosuvastatin Tablets and > Placebo in the JUPITER Trial

Adverse ReactionsPlacebo
N=8,901%
Rosuvastatin tablets 20 mg
N=8,901%
Myalgia6.67.6
Arthralgia3.23.8
Constipation3.03.3
Diabetes mellitus2.32.8
Nausea2.32.4

Pediatric Patients with HeFH

In a 12-week controlled study in pediatric patients 10 to 17 years of age with HeFH with rosuvastatin tablets 5 mg to 20 mg daily [ see Use in Specific Populations ( 8.4) and Clinical Studies ( 14) ], elevations in serum CK greater than 10 x ULN were observed more frequently in rosuvastatin tablets-treated patients compared with patients receiving placebo. Four of 130 (3%) patients treated with rosuvastatin tablets (2 treated with 10 mg and 2 treated with 20 mg) had increased CK greater than 10 x ULN, compared to 0 of 46 patients on placebo.

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of rosuvastatin tablets.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood Disorders: thrombocytopenia

Hepatobiliary Disorders: hepatitis, jaundice, fatal and non-fatal hepatic failure

Musculoskeletal Disorders: arthralgia, rare reports of immune-mediated necrotizing myopathy associated with statin use

Nervous System Disorders: peripheral neuropathy, rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, and confusion) associated with the use of all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks). There have been rare reports of new-onset or exacerbation of myasthenia gravis, including ocular myasthenia, and reports of recurrence when the same or a different statin was administered.

Psychiatric Disorders: depression, sleep disorders (including insomnia and nightmares)

Reproductive System and Breast Disorders: gynecomastia

Respiratory Disorders: interstitial lung disease

Skin and Subcutaneous Tissue Disorders: drug reaction with eosinophilia and systemic symptoms (DRESS), lichenoid drug eruption

7.1 Drug Interactions That Increase The Risk Of Myopathy And Rhabdomyolysis With Rosuvastatin Tablets

Rosuvastatin is a substrate of CYP2C9 and transporters (such as OATP1B1, BCRP).

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. Table 5 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with rosuvastatin tablets and instructions for preventing or managing them [see Warnings and Precautions ( 5.1) and Clinical Pharmacology ( 12.3) ].

Table 5: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Rosuvastatin Tablets

Cyclosporine 

Clinical Impact:

Cyclosporine increased rosuvastatin exposure 7-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine or gemfibrozil with rosuvastatin tablets.  

Intervention:

If used concomitantly, do not exceed a dose of rosuvastatin tablets 5 mg once daily .

Teriflunomide

Clinical Impact:

Teriflunomide increased rosuvastatin exposure more than 2.5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.

Intervention:

In patients taking teriflunomide, do not exceed a dose of rosuvastatin tablets 10 mg once daily .

Enasidenib

Clinical Impact:Enasidenib increased rosuvastatin exposure more than 2.4-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. 
Intervention:In patients taking enasidenib, do not exceed a dose of rosuvastatin tablets 10 mg once daily. 

Capmatinib

Clinical Impact:

Capmatinib increased rosuvastatin exposure more than 2.1-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.

Intervention:

In patients taking capmatinib, do not exceed a dose of rosuvastatin tablets
10 mg once daily .

Fostamatinib

Clinical Impact:

Fostamatinib increased rosuvastatin exposure more than 2.0-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.

Intervention:

In patients taking fostamatinib, do not exceed a dose of rosuvastatin tablets 20 mg once daily .

Febuxostat

Clinical Impact:

Febuxostat increased rosuvastatin exposure more than 1.9-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.

Intervention:

In patients taking febuxostat, do not exceed a dose of rosuvastatin tablets
20 mg once daily .

Gemfibrozil

Clinical Impact:

Gemfibrozil significantly increased rosuvastatin exposure and gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of gemfibrozil with rosuvastatin tablets.

Intervention:

Avoid concomitant use of gemfibrozil with rosuvastatin tablets. If used concomitantly, initiate rosuvastatin tablets at 5 mg once daily and do not exceed a dose of rosuvastatin tablets 10 mg once daily .

Tafamidis

Clinical Impact:

Tafamidis significantly increased rosuvastatin exposure and tafamidis may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of tafamidis with rosuvastatin tablets.

Intervention: 

Avoid concomitant use of tafamidis with rosuvastatin tablets. If used concomitantly, initiate rosuvastatin tablets at 5 mg once daily and do not exceed a dose of rosuvastatin tablets 20 mg once daily. Monitor for signs of myopathy and rhabdomyolysis if used concomitantly with rosuvastatin tablets .

Anti-Viral Medications

Clinical Impact:

Rosuvastatin plasma levels were significantly increased with concomitant administration of many anti-viral drugs, which increases the risk of myopathy and rhabdomyolysis. 

Intervention:

  • Sofosbuvir/velpatasvir/voxilaprevir
  • Ledipasvir/sofosbuvir

Avoid concomitant use with rosuvastatin tablets.

  • Simeprevir
  • Dasabuvir/ombitasvir/paritaprevir/ritonavir
  • Elbasvir/grazoprevir
  • Sofosbuvir/velpatasvir
  • Glecaprevir/pibrentasvir
  • Atazanavir/ritonavir
  • Lopinavir/ritonavir

Initiate with

rosuvastatin tablets
5 mg once daily, and do not exceed a dose of

rosuvastatin tablets
10 mg once daily.

Darolutamide

Clinical Impact:

Darolutamide increased rosuvastatin exposure more than 5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use .

Intervention:

In patients taking darolutamide, do not exceed a dose of rosuvastatin tablets
5 mg once daily .

Regorafenib 

Clinical Impact:

Regorafenib increased rosuvastatin exposure and may increase the risk of myopathy.

Intervention:

In patients taking regorafenib, do not exceed a dose of rosuvastatin tablets
10 mg once daily .

Fenofibrates (e.g., fenofibrate and fenofibric acid)

Clinical Impact:

Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with rosuvastatin tablets.  

Intervention:

Consider if the benefit of using fibrates concomitantly with rosuvastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.

Niacin 

Clinical Impact:

Cases of myopathy and rhabdomyolysis have occurred with concomitant use of lipid-modifying doses (≥1 g/day) of niacin with rosuvastatin tablets.

Intervention:

Consider if the benefit of using lipid-modifying doses (≥1 g/day) of niacin concomitantly with rosuvastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.

Colchicine

Clinical Impact:

Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with rosuvastatin tablets.

Intervention:

Consider if the benefit of using colchicine concomitantly with rosuvastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.

Ticagrelor
Clinical Impact:Concomitant use of rosuvastatin tablets and ticagrelor has been shown to increase rosuvastatin concentrations, which may result in increased risk of myopathy. Cases of myopathy and rhabdomyolysis have been reported in patients using both products concomitantly. Cases have occurred more frequently in patients taking 40 mg of rosuvastatin.

Intervention:

In patients taking concomitant ticagrelor, especially those with additional risk factors for myopathy and rhabdomyolysis, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of rosuvastatin tablets.

7.2 Drug Interactions That Decrease The Efficacy Of Rosuvastatin Tablets

Table 6 presents drug interactions that may decrease the efficacy of rosuvastatin tablets and instructions for preventing or managing them.

Table 6: Drug Interactions that Decrease the Efficacy of Rosuvastatin Tablets

Antacids

Clinical Impact:

Concomitant aluminum and magnesium hydroxide combination antacid administration decreased the mean exposure of rosuvastatin 50% [see Clinical Pharmacology (12.3)].

Intervention:

In patients taking antacid, administer rosuvastatin tablets at least 2 hours before the antacid .

7.3 Rosuvastatin Tablets Effects On Other Drugs

Table 7 presents rosuvastatin tablet's effect on other drugs and instructions for preventing or managing them.

Table 7: Rosuvastatin Tablets Effects on Other Drugs

Warfarin 

Clinical Impact:

Rosuvastatin significantly increased the INR in patients receiving warfarin  [see Clinical Pharmacology (12.3)].

Intervention:

In patients taking warfarin, obtain an INR before starting rosuvastatin tablets and frequently enough after initiation, dose titration or discontinuation to ensure that no significant alteration in INR occurs. Once the INR is stable, monitor INR at regularly recommended intervals. 

8.1 Pregnancy

Risk Summary
Discontinue rosuvastatin tablets when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient.

Rosuvastatin tablets decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, rosuvastatin tablets may cause fetal harm when administered to pregnant patients based on the mechanism of action [ see Clinical Pharmacology ( 12.1) ]. In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients.

Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. Published data from prospective and retrospective observational cohort studies with rosuvastatin tablets use in pregnant women are insufficient to determine if there is a drug-associated risk of miscarriage ( see Data).

In animal reproduction studies, no adverse developmental effects were observed in pregnant rats or rabbits orally administered rosuvastatin during the period of organogenesis at doses that resulted in systemic exposures equivalent to human exposures at the maximum recommended human dose (MRHD) of 40 mg/day, based on AUC and body surface area (mg/m 2), respectively ( see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Human Data

A Medicaid cohort linkage study of 1,152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders – including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods. The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births.

Animal Data

In female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to gestation day 7 resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10 times the human exposure at the MRHD dose of 40 mg/day based on AUC).

In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day 7 through lactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD of 40 mg/day based body surface area).

In pregnant rabbits given 0.3, 1, and 3 mg/kg/day of rosuvastatin from gestation day 6 to day 18, decreased fetal viability and maternal mortality was observed at 3 mg/kg/day (dose equivalent to the MRHD of 40 mg/day based on body surface area).

Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following a single 25 mg/kg oral gavage dose on gestation day 16 in rats. In rabbits, fetal tissue distribution was 25% of maternal plasma concentration after a single oral gavage dose of 1 mg/kg on gestation day 18.

8.2 Lactation

Risk Summary
Limited data from case reports in published literature indicate that rosuvastatin is present in human milk. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Statins, including rosuvastatin, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant.

Because of the potential for serious adverse reactions in a breastfed infant, based on the mechanism of action, advise patients that breastfeeding is not recommended during treatment with rosuvastatin tablets. [ seeUse in Specific Populations ( 8.1)and Clinical Pharmacology ( 12.1) ].

8.4 Pediatric Use

The safety and effectiveness of rosuvastatin tablets as an adjunct to diet to reduce LDL-C have been established in pediatric patients 8 years of age and older with HeFH. Use of rosuvastatin tablets for this indication is based on one 12-week controlled trial with a 40-week open-label extension period in 176 pediatric patients 10 years of age and older with HeFH and one 2-year open-label, uncontrolled trial in 175 pediatric patients 8 years of age and older with HeFH [see  ClinicalStudies( 14) ]. In the 1-year trial with a 12-week controlled phase, there was no detectable effect of rosuvastatin tablets on growth, weight, BMI (body mass index), or sexual maturation in patients aged 10 to 17 years.

The safety and effectiveness of rosuvastatin tablets as an adjunct to other LDL-C-lowering therapies to reduce LDL-C have been established in pediatric patients 7 years of age and older with HoFH. Use of rosuvastatin tablets for this indication is based on a randomized, placebo-controlled, cross-over study in 14 pediatric patients 7 years of age and older with HoFH [see  Clinical Studies ( 14) ] .

The safety and effectiveness of rosuvastatin tablets have not been established in pediatric patients younger than 8 years of age with HeFH, younger than 7 years of age with HoFH, or in pediatric patients with other types of hyperlipidemia (other than HeFH or HoFH).

8.5 Geriatric Use

Of the 10,275 patients in clinical studies with rosuvastatin tablets, 3,159 (31%) were 65 years and older, and 698 (6.8%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.

Advanced age (≥65 years) is a risk factor for rosuvastatin tablets-associated myopathy and rhabdomyolysis. Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving rosuvastatin tablets for the increased risk of myopathy [see Warnings and Precautions ( 5.1)] .

8.6 Renal Impairment

Rosuvastatin exposure is not influenced by mild to moderate renal impairment (CL cr≥30 mL/min/1.73 m 2). Exposure to rosuvastatin is increased to a clinically significant extent in patients with severe renal impairment (CL cr<30 mL/min/1.73 m 2) who are not receiving hemodialysis [see Clinical Pharmacology ( 12.3) ].

Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. In patients with severe renal impairment not on hemodialysis, the recommended starting dosage is 5 mg daily and should not exceed 10 mg daily [see Dosage and Administration ( 2.5) and Warnings and Precautions ( 5.1) ].

8.7 Hepatic Impairment

Rosuvastatin tablets are contraindicated in patients with acute liver failure or decompensated cirrhosis.Chronic alcohol liver disease is known to increase rosuvastatin exposure. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [see Contraindications ( 4), Warning and Precautions ( 5.3) and Clinical Pharmacology ( 12.3) ].

8.8 Asian Patients

Pharmacokinetic studies have demonstrated an approximate 2-fold increase in median exposure to rosuvastatin in Asian subjects when compared with White controls. Adjust the rosuvastatin tablets dosage in Asian patients [see Dosage and Administration ( 2.4) and Clinical Pharmacology ( 12.3) ].

10 Overdosage

No specific antidotes for rosuvastatin tablets are known. Hemodialysis does not significantly enhance clearance of rosuvastatin. In the event of overdose, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.

11 Description

Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor.

The chemical name for rosuvastatin calcium USP is bis[(E)-7-[4- (4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S) -3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula:

Structure (Image Structure)

Structure (Image Structure)

The empirical formula for rosuvastatin calcium USP is (C 22H 27FN 3O 6S) 2Ca and the molecular weight is 1001.14. Rosuvastatin calcium is a white amorphous powder that is sparingly soluble in water and methanol, and slightly soluble in ethanol. Rosuvastatin calcium is a hydrophilic compound with a partition coefficient (octanol/water) of 0.13 at pH of 7.0.

Rosuvastatin tablets for oral use contain rosuvastatin 5 mg, 10 mg, 20 mg, or 40 mg (equivalent to 5.2 mg, 10.4 mg, 20.8 mg, and 41.6 mg rosuvastatin calcium) and the following inactive ingredients: Each tablet contains: crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, titanium dioxide and triacetin. Additionally, the 5 mg tablet contains ferric oxide yellow and the 10 mg, 20 mg and 40 mg tablets contain ferric oxide red.

12.1 Mechanism Of Action

Rosuvastatin is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.

12.2 Pharmacodynamics

Inhibition of HMG-CoA reductase by rosuvastatin accelerates the expression of LDL-receptors, followed by the uptake of LDL-C from blood to the liver, leading to a decrease in plasma LDL-C and total cholesterol. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very-low-density lipoproteins. The maximum LDL-C reduction of rosuvastatin tablets are usually achieved by 4 weeks and is maintained after that.

12.3 Pharmacokinetics

Absorption

In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5 hours following oral dosing. Both C maxand AUC increased in approximate proportion to rosuvastatin tablet dose. The absolute bioavailability of rosuvastatin is approximately 20%. The AUC of rosuvastatin does not differ following evening or morning drug administration.

Effect of food

Administration of rosuvastatin tablets with food did not affect the AUC of rosuvastatin.

Distribution

Mean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma concentrations.

Elimination

Metabolism

Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 \ 2C9, and in vitrostudies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by the parent compound.

Excretion

Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route. The elimination half-life of rosuvastatin is approximately 19 hours.

Specific Populations

Geriatric Patients

There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age ≥65 years).

Pediatric Patients

In a population pharmacokinetic analysis of two pediatric trials involving patients with HeFH 10 to 17 years of age and 8 to 17 years of age, respectively, rosuvastatin exposure appeared comparable to or lower than rosuvastatin exposure in adult patients.


Male and Female Patients

There were no differences in plasma concentrations of rosuvastatin between males and females.


Racial or Ethnic Groups

A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among White, Hispanic, or Latino ethnicity, and Black or Afro-Caribbean groups. However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate 2-fold elevation in median exposure (AUC and Cmax) in Asian subjects when compared with a White control group.

Patients with Renal Impairment

Mild to moderate renal impairment (CL cr≥30 mL/min/1.73 m 2) had no influence on plasma concentrations of rosuvastatin. However, plasma concentrations of rosuvastatin increased to a clinically significant extent (about 3-fold) in patients with severe renal impairment (CL cr<30 mL/min/1.73 m 2) not receiving hemodialysis compared with healthy subjects (CL cr>80 mL/min/1.73 m 2).

Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function.

Patients with Hepatic Impairment

In patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased.

In patients with Child-Pugh A disease, C maxand AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function. In patients with Child-Pugh B disease, C maxand AUC were increased 100% and 21%, respectively, compared with patients with normal liver function.

Drug Interaction Studies

Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent.

Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP). Concomitant administration of rosuvastatin tablets with medications that are inhibitors of these transporter proteins (e.g., cyclosporine, certain HIV protease inhibitors [see Dosage and Administration (2.6)and Drug Interactions (7.1)] and ticagrelor [see Drug Interactions (7.1)] ) may result in increased rosuvastatin plasma concentrations.

Table 8: Effect of Coadministered Drugs on Rosuvastatin Systemic Exposure

QD= Once daily, BID= Twice daily, TID= Three times daily, QID= Four times daily

1Single dose unless otherwise noted.

2Clinically significant [ see Dosage and Administration( 2)and Warnings and Precautions( 5) ]

3Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7 = 30% decrease,  11=11-fold increase in exposure)

  Coadministered drug and dosing regimenRosuvastatin
Mean Ratio
 (ratio with/without coadministered drug)
 No Effect = 1.0
Dose (mg) 1Change in
AUC
Change in C max
Sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/100 mg) + Voxilaprevir (100 mg) once daily for 15 days10mg, single dose7.39 2
(6.68 to 8.18) 3
18.88 2
(16.23 to 21.96) 3
Cyclosporine – stable dose required
 (75 mg - 200 mg BID)
10 mg, QD for
10 days
7.1 211 2
Darolutamide 600 mg BID, 5 days5mg, single dose5.2 2~5 2
Regorafenib 160 mg QD, 14 days5 mg, single dose3.8 24.6 2
Atazanavir/ritonavir combination 300 mg/100 mg QD for 8 days10 mg3.1 2 7 2
Simeprevir 150 mg QD, 7 days10 mg, single
dose
2.8 2
(2.3 to 3.4) 3
3.2 2
 (2.6 to 3.9) 3
Velpatasvir 100 mg once daily10 mg, single dose2.69 2
(2.46 to 2.94) 3
2.61 2
(2.32 to 2.92) 3
Ombitasvir 25mg/paritaprevir 150mg/ ritonavir 100mg + dasabuvir 400 mg BID5mg, single dose2.59 2
(2.09 to 3.21) 3
7.13 2
(5.11 to 9.96) 3
TeriflunomideNot available2.51 22.65 2
Enasidenib 100 mg QD, 28 days

10 mg, single dose

2.443.66
Elbasvir 50 mg/grazoprevir 200mg once daily10mg, single dose2.26 2
(1.89 to 2.69) 3
5.49 2
(4.29 to 7.04) 3
Glecaprevir 400 mg/pibrentasvir 120mg once daily5mg, once daily2.15 2
(1.88 to 2.46) 3
5.62 2
(4.80-6.59) 3
Lopinavir/ritonavir combination
400 mg/100 mg BID for 17 days
20 mg, QD for
7 days
2.1 2
(1.7 to 2.6) 3
5 2
(3.4 to 6.4) 3
Capmatinib 400 mg BID10 mg, single dose2.08 2
(1.56 to 2.76) 3
3.04 2
(2.36 to 3.92) 3
Fostamatinib 100 mg BID20 mg, single dose1.96 2
(1.77 to 2.15) 3
1.88 2
(1.69 to 2.09) 3
Febuxostat 120 mg QD for 4 days10 mg, single dose1.9 2
(1.5 to 2.5) 3
2.1 2
(1.8 to 2.6) 3
Gemfibrozil 600 mg BID for 7  days80 mg1.9 2
(1.6 to 2.2) 3
2.2 2
(1.8 to 2.7) 3
Tafamidis 61 mg BID on Days 1 & 2, followed by QD on Days 3 to 910 mg1.97 2
(1.68 to 2.31) 3
1.86 2
(1.59 to 2.16) 3
Eltrombopag 75 mg QD, 5 days10 mg1.6
(1.4 to 1.7) 3
2
(1.8 to 2.3) 3
Darunavir 600 mg/ritonavir 100 mg BID, 7 days10 mg, QD for 7
days
1.5
(1.0 to 2.1) 3
2.4
(1.6 to 3.6) 3
Tipranavir/ritonavir combination
 500 mg/200mg BID for 11 days
10 mg1.4
 (1.2 to 1.6) 3
2.2
(1.8 to 2.7) 3
Dronedarone 400 mg BID10 mg1.4
Itraconazole 200 mg QD, 5 days10 mg or 80 mg1.4
(1.2 to 1.6) 3
1.3
(1.1 to 1.4) 3
1.4
(1.2 to 1.5) 3
1.2
(0.9 to 1.4) 3
Ezetimibe 10 mg QD, 14 days10 mg, QD for
14 days
1.2
(0.9 to 1.6) 3
1.2
(0.8 to 1.6) 3
Fosamprenavir/ritonavir 700
 mg/100 mg BID for 7 days
10 mg1.11.5
Fenofibrate 67 mg TID for 7 days10 mg↔1.2
(1.1 to 1.3) 3
Rifampicin 450 mg QD, 7 days20 mg↔
Aluminum & magnesium
hydroxide combination antacid
Administered simultaneously
Administered 2 hours apart

40 mg
40 mg
0.5 2
(0.4 to 0.5) 3
0.8
(0.7 to 0.9) 3
0.5 2
(0.4 to 0.6) 3
0.8
(0.7 to 1.0) 3
Ketoconazole 200 mg BID for 7 days80 mg1.0
(0.8 to 1.2) 3
1.0
(0.7 to 1.3) 3
Fluconazole 200 mg QD for 11 days80 mg1.1
(1.0 to 1.3) 3
1.1
(0.9 to 1.4) 3
Erythromycin 500 mg QID for 7 days80 mg0.8
(0.7 to 0.9) 3
0.7
(0.5 to 0.9) 3

Table 9: Effect of Rosuvastatin Coadministration on Systemic Exposure to Other Drugs

Rosuvastatin Dosage RegimenCoadministered Drug
Mean Ratio
(ratio with/without coadministered drug)
No Effect=1.0
Name and DoseChange in
AUC
Change in
C max
40 mg QD for 10 daysWarfarin 1
25 mg single dose
R-Warfarin 1.0
(1.0 to 1.1) 2
S-Warfarin 1.1
(1.0 to 1.1) 2
R-Warfarin 1.0
(0.9 to 1.0) 2
S-Warfarin 1.0
(0.9 to1.1) 2
40 mg QD for 12 daysDigoxin
0.5 mg single dose
1.0
(0.9 to 1.2) 2
1.0
(0.9 to 1.2) 2
40 mg QD for 28 daysOral Contraceptive
(ethinyl estradiol 0.035 mg & norgestrel 0.180, 0.215 and 0.250 mg) QD for 21 Days
EE 1.3
(1.2 to 1.3) 2NG 1.3
(1.3 to 1.4) 2
EE 1.3
(1.2 to 1.3) 2
NG 1.2
 (1.1 to 1.3) 2

EE = ethinyl estradiol, NG = norgestrel,QD= Once daily

1Clinically significant pharmacodynamic effects [seeDrug Interactions ( 7.3) ]

2Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7=30% decrease, 11=11-fold increase in exposure)

12.5 Pharmacogenomics

Disposition of rosuvastatin, involves OATP1B1 and other transporter proteins. Higher plasma concentrations of rosuvastatin have been reported in very small groups of patients (n=3 to 5) who have two reduced function alleles of the gene that encodes OATP1B1 ( SLCO1B1521T > C). The frequency of this genotype (i.e., SLCO1B1521 C/C) is generally lower than 5% in most racial/ethnic groups. The impact of this polymorphism on efficacy and/or safety of rosuvastatin tablets have not been clearly established.

13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage, the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Increased incidence of polyps was not seen at lower doses.

In a 107-week carcinogenicity study in mice given 10, 60, or 200 mg/kg/day by oral gavage, an increased incidence of hepatocellular adenoma/carcinoma was observed at 200 mg/kg/day at systemic exposures 20 times the human exposure at 40 mg/day based on AUC. An increased incidence of hepatocellular tumors was not seen at lower doses.

Rosuvastatin was not mutagenic or clastogenic with or without metabolic activation in the Ames test with Salmonella typhimuriumand Escherichia coli, the mouse lymphoma assay, and the chromosomal aberration assay in Chinese hamster lung cells. Rosuvastatin was negative in the in vivomouse micronucleus test.

In rat fertility studies with oral gavage doses of 5, 15, 50 mg/kg/day, males were treated for 9 weeks prior to and throughout mating and females were treated 2 weeks prior to mating and throughout mating until gestation day 7. No adverse effect on fertility was observed at 50 mg/kg/day (systemic exposures up to 10 times the human exposure at 40 mg/day based on AUC). In testicles of dogs treated with rosuvastatin at 30 mg/kg/day for one month, spermatidic giant cells were seen. Spermatidic giant cells were observed in monkeys after 6-month treatment at 30 mg/kg/day in addition to vacuolation of seminiferous tubular epithelium. Exposures in the dog were 20 times and in the monkey 10 times the human exposure at 40 mg/day based on body surface area. Similar findings have been seen with other drugs in this class.

16 How Supplied/Storage And Handling

Rosuvastatin tablets USP are supplied as:

Rosuvastatin tablets USP, 5 mg are yellow colored, round, biconvex, film coated tablets debossed with '79' on one side and plain on other side.

Bottles of 30 NDC 51655-756-52

Storage

Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from moisture.

17 Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Myopathy and Rhabdomyolysis

Advise patients that rosuvastatin tablets may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over-the-counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever [ see Warnings and Precautions ( 5.1) , and Drug Interactions ( 7.1) ].

Hepatic Dysfunction

Inform patients that rosuvastatin tablets may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice [ see Warnings and Precautions ( 5.3) ].

Increases in HbA1c and Fasting Serum Glucose Levels

Inform patients that increases in HbA1c and fasting serum glucose levels may occur with rosuvastatin tablets. Encourage patients to optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices [ see Warnings and Precautions ( 5.5) ].

Pregnancy

Advise pregnant patients and patients who can become pregnant of the potential risk to a fetus. Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss if rosuvastatin tablets should be discontinued [ see Use in Specific Populations ( 8.1) ].

Lactation

Advise patients that breastfeeding during treatment with rosuvastatin tablet is not recommended [ see Use in Specific Populations ( 8.2) ].

Concomitant Use of Antacids

When taking rosuvastatin tablets with an aluminum and magnesium hydroxide combination antacid, administer rosuvastatin tablets at least 2 hours before the antacid [ see Drug Interactions ( 7.2) ].

Missed Doses

If a dose is missed, advise patients not to take an extra dose. Just resume the usual schedule [see Dosage and Administration( 2.1) ].

Trademarks are the property of their respective owners.

Dispense with Patient Information available at: https://torrentpharma.com/pi/usa/products/

Logo (Image Torrentpi Logo)

Logo (Image Torrentpi Logo)

Manufactured by:

Torrent Pharmaceuticals LTD., India.

Manufactured for:

Torrent Pharma INC., Basking Ridge, NJ 07920.

8097730                                                             Revised: September 2024

* Please review the disclaimer below.